Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial
作者机构：Department of OphthalmologyKayseri Acibadem HospitalKayseri 38030Turkey
出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)
年 卷 期：2020年第13卷第9期
页 面：1423-1429页
核心收录：
学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学]
主 题：cell mediated therapy retinitis pigmentosa suprachoroidal umbilical cord derived mesenchymal stem cells visual function
摘 要：AIM:To investigate the efficacy and the safety of umbilical cord derived mesenchymal stem cell(UC-MSC)implantation in patients with retinitis pigmentosa(RP).METHODS:This prospective,single-center,phase 3 clinical study enrolled 124 eyes of 82 RP *** patients received 5 million UC-MSCs to the suprachoroidal area with a surgical *** were evaluated on the 1st day,1st,and 6th months *** corrected visual acuity(BCVA),anterior segment and fundus examinations,color photography,optical coherence tomography(OCT),and visual field(VF)tests were carried out at each *** fluorescein angiography(FFA)and multifocal electroretinography(mfERG)recordings were performed at the end of the 6th *** and systemic adverse events of the surgical procedure were also ***:All of the 82 patients completed the 6-month follow-up *** of them had any serious systemic or ocular *** were statistically significant improvements in BCVA and VF during the study(all P0.05).The amplitudes of the P1 waves in the central areas showed significant improvements in mfERG *** were also significant increases in implicit times of P1 waves in the central ***:Suprachoroidal administration of UC-MSCs has beneficial effect on BCVA,VF,and mfERG measurements during the 6-month follow-up *** mediated therapy based on the secretion of growth factors(GFs)seems to be an effective and safe option for degenerative retinal diseases.
维普期刊数据库